Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

PSA levels help determine prostate size and guide treatment choices for benign prostatic hyperplasia.

This study concludes that the accuracy of PSA testing for prostate cancer diagnosis is not only maintained but may be increased when used alongside 5-alpha reductase inhibitors like finasteride and dutasteride.

This review discusses the potential use of prostate specific antigen as a diagnostic marker for hyperandrogenism in polycystic ovary syndrome but reports no new clinical results and calls for further research.

This study found that increased PSA levels in women with hyperandrogenism may serve as a diagnostic marker, comparable to free testosterone levels.

This erratum addresses the long-term effects of finasteride on prostate-specific antigen levels but reports no new research findings.

This study observed that although 5-alpha-reductase inhibitors reduce PSA density in patients on active surveillance for prostate cancer, those who progress to more serious disease still show higher PSA densities, suggesting these inhibitors accentuate differences in clinically significant cases.

In this paper, three APS patients were followed over time, showing that the diagnosis and course of autoimmune polyglandular syndrome can evolve, highlighting the need for careful monitoring and potential re-evaluation.

This study observed that women with PCOS from Khyber Pakhtunkhwa had significantly higher serum PSA levels, which positively correlated with hirsutism, testosterone, and DHEAS levels compared to healthy controls.

This study found that IsoPSA's ability to detect both any prostate cancer and clinically actionable prostate cancer remains unaffected by medications like 5-ARIs and α-blockers, which are commonly used to treat benign prostatic hyperplasia symptoms.

In this study, serum PSA levels were higher in women with PCOS, suggesting it may serve as a marker for hyperandrogenism in this condition.

This presentation argues that post-exposure syndromes like PSSD and Long COVID form a coherent group of conditions driven by complex interactions in high-dimensional state spaces rather than singular molecular pathways.

This study reports two cases where localized prostate cancer with low PSA levels was incidentally detected through CT scans performed for other medical reasons.

This case report documents successful virilization, including penile length increase, in a boy with partial androgen insensitivity syndrome using high-dose testosterone combined with anastrozole.

This study found that testosterone replacement therapy, especially intramuscular administration, significantly increased PSA levels compared to placebo, while a significant correlation between PSA and testosterone was observed in non-BPH patients.

PSA testing is a reliable method for detecting prostate cancer, and opioids may lower PSA levels, but triglycerides don't affect prostate cancer risk.

This study found that a 3 mm margin around the prostate CTV may be adequate if accompanied by frequent imaging, but superior-inferior displacements were notably greater than in other directions.

This study concluded that incorporating the percentage of free PSA and urinary markers improves the accuracy of determining the need for prostate biopsy.

In this study, PSA levels were significantly lower among African-American men with higher C-peptide levels and Caucasian men with higher HbA1c levels, suggesting a link between metabolic markers and prostate cancer detection.

This study examines how conditions like PSSD, Long COVID, and ME/CFS form a "Post-Exposure Syndromes" family, initiated by transient exposures but persisting due to complex state-space dynamics, and suggests improving pharmacovigilance to better address and understand these persistent syndromes.

This article discusses the implications of finasteride on serum PSA levels and questions the routine recommendation for prostate biopsy at specific PSA thresholds, urging reevaluation of prostate cancer detection methods; it reports no clinical results.

This study reports that three synthesized PSMA-targeted radioimaging agents demonstrated high affinity and specific localization to prostate cancer tumors in a mouse model, highlighting their potential for cancer detection and monitoring.

Clear definitions and strategies are needed to manage long-term COVID-19 symptoms effectively.

This study found that men without prostate cancer carrying the A-allele of SNP rs1204038 had a 65% higher risk of PSA levels above 3 ng/mL compared to those with the G-allele, increasing referrals for further examination.

This study observed that finasteride therapy reduced PSA levels by about 40% over a year in Chinese patients with benign prostatic hyperplasia, with varying effects based on baseline PSA levels.

This study suggests that using the International Psoriasis Council's classification, which includes body surface area, special areas, and treatment history, may identify more candidates for systemic therapy than by body surface area alone.

This retrospective study observed no significant difference in the prevalence of incidental prostate cancer between suprapubic prostatectomy and transurethral prostate resection groups, with most tumors being well differentiated and early-stage.

This review discusses how 5α-reductase inhibitors affect PSA levels in benign prostatic hyperplasia treatment and their role in prostate cancer screening, but reports no new clinical findings.

This study modeled how differences in trial settings and protocols, such as biopsy compliance and control arm screening, can explain the varying prostate cancer mortality reductions observed in the ERSPC and PLCO trials.